Paris‑based biotech firm Abivax exercised its underwriters’ option, increasing the size of its American Depositary Share offering and outlining a clear plan for the newly‑raised capital.
Abivax SA announced on July 2, 2026 that the underwriters handling its recent public offering of American Depositary Shares (ADSs) have taken up the entire over‑allotment option. The option, which allowed the syndicate to purchase up to 15 % more ADSs than initially sold, was exercised for the full 960,000 additional units. Combined with the original 6,400,000 ADSs, the transaction now totals 7,360,000 ADSs, representing a gross inflow of roughly $920.0 million (€807.4 million). After accounting for underwriting fees and estimated offering expenses, the net proceeds are projected at about $874.1 million (€767.1 million).
The additional ADSs will be delivered at the same time as the original closing, which the company expects to finalize on July 6, 2026. The pricing of the extra shares was set at $125.00 per ADS, equivalent to €109.71 per ordinary share based on the European Central Bank’s June 30 exchange rate of €1 = $1.1394. This price mirrors the volume‑weighted average price (VWAP) of Abivax’s ordinary shares on Euronext Paris over the three‑day window from June 26 to June 30, plus a modest premium of 2.39 %. The pricing decision was delegated to the chief executive officer under the authority granted by the 18th and 27th resolutions of the company’s combined shareholders’ meeting on May 11, 2026.
Abivax’s ADSs trade on the Nasdaq Global Market under the ticker “ABVX,” while the ordinary shares are listed on Euronext Paris under the same symbol. The dual‑listing strategy gives the firm access to both U.S. institutional investors and European capital markets, a common approach for biotech companies seeking broad exposure.
In a brief statement, the stabilizing agent Leerink Partners confirmed that no stabilization activity was required and that the stabilization period has officially ended. This signals that the market absorbed the offering without the need for price support, an encouraging sign for liquidity.
The proceeds are earmarked for three primary purposes. First, the company plans to fund activities related to the potential launch of obefazimod, its lead candidate targeting inflammatory disorders, in the United States. Second, a substantial portion will be directed toward ongoing clinical research, particularly studies focused on ulcerative colitis and Crohn’s disease—areas where Abivax has already reported encouraging early‑phase data. Any remaining funds will be allocated to general corporate needs, which may include working capital, debt repayment, or strategic acquisitions.
Abivax’s filing history supports the current offering. An automatic shelf registration statement on Form F‑3, which includes a prospectus, was initially filed with the U.S. Securities and Exchange Commission on July 23, 2025 and became effective upon filing. The registration was subsequently amended on June 30, 2026 to reflect the expanded offering. The company intends to submit a final prospectus supplement describing the terms of the ADS issuance. All related documents are available free of charge through the SEC’s EDGAR system, and copies can also be requested from the participating underwriters—Leerink Partners, Morgan Stanley & Co., Piper Sandler & Co., and Guggenheim Securities.
While the financial details dominate the announcement, the broader context is equally noteworthy. The biotech sector has seen a resurgence of public‑market funding after a period of cautious investor sentiment, and Abivax’s ability to secure a $920 million raise underscores continued appetite for innovative immunomodulatory therapies. The company’s focus on obefazimod—a small‑molecule inhibitor designed to restore immune tolerance—places it among a growing cohort of firms pursuing oral alternatives to biologics for chronic inflammatory diseases. If the U.S. commercialization plan proceeds as outlined, Abivax could join the ranks of biotech firms that have successfully transitioned from early‑stage research to market‑ready products, potentially reshaping treatment paradigms for conditions that affect millions worldwide.
The forward‑looking nature of the release is underscored by a standard disclaimer. Abivax cautions investors that statements regarding the expected closing date, use of proceeds, and other projections are subject to a range of risks—including market volatility, regulatory hurdles, and the achievement of customary closing conditions for the additional ADSs. The company references its universal registration document filed with the French Autorité des marchés financiers (AMF) and its Form 20‑F annual report filed with the SEC on March 23, 2026 for a comprehensive list of risk factors.
Legally, the press release does not constitute an offer to sell securities, nor does it solicit such an offer, in any jurisdiction where doing so would be unlawful without registration. Distribution of the announcement may be limited in certain regions, and recipients are advised to verify local compliance requirements. The communication is intended solely for qualified investors as defined by the Prospectus Regulation and, in the United Kingdom, for persons meeting the criteria of the Public Offers and Admissions to Trading Regulations 2024. No prospectus has been published, and the offering is being made under an exemption that does not require a public prospectus in the European Economic Area.
In summary, Abivax’s full exercise of the over‑allotment option not only expands its capital base but also signals confidence from the underwriting syndicate in the company’s pipeline and commercial strategy. The additional funding will accelerate the U.S. rollout of obefazimod, advance pivotal clinical trials, and provide flexibility for broader corporate initiatives. As the biotech financing landscape continues to evolve, Abivax’s move may serve as a bellwether for other mid‑stage companies seeking to leverage both European and U.S. markets to fund the next generation of immunotherapies.
Get in touch with our Adtech experts
